2012 Tuberous Sclerosis Complex Clinical Trial Award Program
Page 2

With this, the funding agency requires the proposals to be submitted under this program to focus on the following areas:

a) The studies of the pathogenesis, disease severity prediction and diversity of symptoms that affects a patient's cognition, behavior, sleep, renal and pulmonary functions, along with the signs and symptoms of epilepsy and autism

b) The studies regarding the impact of TSC manifestations over the lifespan of a patient

c) The determination of novel strategies for the management and prevention of TSC manifestations including early therapeutic approaches

d) The deep comprehension of the cellular and molecular mechanisms of TSC developmental stages in mammalian and non-mammalian systems

e) Genetic, epigenetic, and non-genetic modifiers of TSC

f) The identification of biomarkers for early detection, prognosis, and prediction of TSC treatment outcomes.

To support this activities covered under this initiative, the Department of Defense is willing to administer funds in the amount of $1,600,000 per year, for a maximum project period of up to 4 years.

Assistant Professors or Lead Professors at Accredited Colleges and Universities are encouraged to submit an application under the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program.

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on community grants and health grants.

Additional Resources

category - Health Grants

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

Leadership Group for a Clinical Research Network on Antibacterial Resistance Program
In line with this mission, the National Institutes of Health has collaborated with the National Institute of Allergy and Infectious Diseases (NIAID) in an attempt to establish the Leadership Group for a Clinical Research Network on Antibacterial Resistance Program.

---

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

---

National Institutes of Health funds the Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults
The National Institutes of Health has recently established a program entitled Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults wherein they intend to kick-off research studies that will create, implement, and evaluate both old and new interventions that are geared towards improving adherence to medical and behavioral regimens for HIV-positive adolescents which are 11 to 21 years old and adults who are 21 to 24 years old.

---